Poseida Therapeutics (PSTX) has filed a new preliminary prospectus for a $115M IPO.
The San Diego, CA-based biotech develops cell and
gene therapies based on its proprietary platforms, including its
non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific
gene editing system and nanoparticle- and AAV-based gene delivery
technologies.
Lead candidate is Phase 2-stage
P-BCMA-101, an autologous CAR-T therapy for the potential treatment of
multiple myeloma. If the results are positive, the data may be
sufficient to support accelerated approval in the U.S.
Candidate #2 is Phase 1-stage P-PSMA-101, an autologous CAR-T for castration-resistant prostate cancer.
2019 Financials: Operating Expenses: $85.5M (+104%); Net Loss: ($86.5M) (-95%); Cash Burn: ($64.4M) (-69%).
The company was on deck for its U.S. debut in January 2019 but pulled back after raising $142M in a series C round including $75M from Novartis (NYSE:NVS).
https://seekingalpha.com/news/3584758-poseida-therapeutics-steps-back-box-for-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.